シンダックス・ファーマシューティカルズに関するコメント

$シンダックス・ファーマシューティカルズ(SNDX.US)$ Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment
MT Newswires· 1 min ago
Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer.
The company said the filing was assigned a prescription drug user fee act target action date of S...

$シンダックス・ファーマシューティカルズ(SNDX.US)$ Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
3 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE

$シンダックス・ファーマシューティカルズ(SNDX.US)$ See a lot of potential here? with price action after trial PR, its like everyone read ( trial stopped early ) but didn’t read any further? it was stopped for efficacy, it showed improvement and are moving on to next phase!

$バイオノミックス(BNOX.US)$$フェマシス(FEMY.US)$  $シンダックス・ファーマシューティカルズ(SNDX.US)$ stocks that will be seeing big action today

Implied volatility is a measure of the market's expectation of the potential price movements of the stock in the future. Here are the stocks with the most notable implied volatility today.
$シンダックス・ファーマシューティカルズ(SNDX.US)$ experienced a 7.10% decline in its stock price during the previous trading session, accompanied by high options activity. The company's option volume reached 36.97K with an IV percentile of 100% and implied volatility ...

Implied volatility is a measure of the market's expectation of the potential price movements of the stock in the future. Here are the stocks with the most notable implied volatility today.
$シンダックス・ファーマシューティカルズ(SNDX.US)$ experienced a 3.30% increase in stock price during the previous trading session, accompanied by high options activity. The company's option volume peaked at 49.82K with an IV percentile of 94% and a current implied vol...